{"id":"W3010122169","doi":"10.1002/path.5406","title":"The path to a better biomarker: application of a risk management framework for the implementation of PD‐L1 and TILs as immuno‐oncology biomarkers in breast cancer clinical trials and daily practice","year":2020,"lang":"en","type":"review","venue":"The Journal of Pathology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":226,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia; Ontario Institute for Cancer Research; BC Cancer Agency","funders":"Chugai Pharmaceutical; Genentech; National Breast Cancer Foundation; Puma Biotechnology; Novartis Pharma; EMD Serono; Mersana Therapeutics; Incyte; Taiho Pharmaceutical; Genomic Health; Daiichi Sankyo Europe; Breast Cancer Research Foundation; World Health Organization; GlaxoSmithKline; Celgene; Bayer; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Amgen; Pfizer","keywords":"Medicine; Oncology; Breast cancer; Biomarker; Clinical Practice; Internal medicine; Clinical trial; Clinical Oncology; Cancer; Medical physics; Family medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.3174296,0.002849216,0.00472015,0.007570753,0.003292014,0.01924409,0.00620744,0.009908504,0.004013652],"category_scores_gemma":[0.3025664,0.001790074,0.003420787,0.003752933,0.01626729,0.01700533,0.01289232,0.01760618,0.002103128],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.009779517,"about_ca_system_score_gemma":0.03274572,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003940362,"about_ca_topic_score_gemma":0.003193889,"domain_scores_codex":[0.751102,0.2009841,0.01411689,0.009446984,0.02199421,0.002355841],"domain_scores_gemma":[0.7263666,0.179065,0.02662305,0.01520467,0.04359436,0.009146223],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001093996,0.0006571616,0.01516045,0.002724807,0.001045263,0.000405879,0.002797562,0.01696577,0.001436148,0.5102749,0.05297696,0.3944612],"study_design_scores_gemma":[0.0006309392,0.001773809,0.004126949,0.004673298,0.0007662257,0.0005992276,0.001163077,0.04670327,0.001759514,0.8239126,0.1134521,0.0004390886],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"methods","genre_gemma":"review","genre_scores_codex":[0.00374486,0.01819913,0.637651,0.3256591,0.002503135,0.001741645,0.0003971292,0.0007121482,0.009391835],"genre_scores_gemma":[0.1271862,0.0082188,0.8076231,0.04415463,0.005500732,0.004524405,0.0003855302,0.0002784659,0.002128088],"genre_candidate":"review","genre_consensus":null,"teacher_disagreement_score":0.3174296,"threshold_uncertainty_score":0.8417308,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0819935595309814,"score_gpt":0.5147935023912429,"score_spread":0.4327999428602615,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}